[PDF] Top 20 Drug response to PD-1/PD-L1 blockade: based on biomarkers
Has 10000 "Drug response to PD-1/PD-L1 blockade: based on biomarkers" found on our website. Below are the top 20 most common "Drug response to PD-1/PD-L1 blockade: based on biomarkers".
Drug response to PD-1/PD-L1 blockade: based on biomarkers
... of PD-L1 expression needs complicated considerations of tumor types and standardization, and sometimes it is not sufficient to differentiate responders from ...Hence, PD-L1 single-nucleotide ... See full document
11
Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series
... to PD-1 or PD-L1 inhibitors, there may be situations where re-treatment has plausible ...with PD-1 blockade may be especially effective in patients who discontinue the ... See full document
5
Contribution of NK cells to immunotherapy mediated by PD 1/PD L1 blockade
... model based on ...of PD-L1 in vitro, which was strongly upregulated by IFN-γ (Figure ...of PD-1 inhibition in this tumor model, we generated a PD-L1–deficient variant of ... See full document
16
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
... improved response to PD-L1 inhibition was noted [55, ...Similarly, blockade of mutated BRAF and MEK was associated with improved response to PD-1/PD-L1 in- ... See full document
6
The therapeutic promise of disrupting the PD-1/PD-L1 immune checkpoint in cancer: unleashing the CD8 T cell mediated anti-tumor activity results in significant, unprecedented clinical efficacy in various solid tumors
... Antibody-mediated blockade of co-inhibitory receptors has been shown to restore T cell function in both chronic viral infections and ...or PD-1 have recently been approved for the treatment of ... See full document
5
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
... checkpoint blockade immunotherapies result in durable clinical responses through the induction, activa- tion, and expansion of tumor-specific cytotoxic T ...and PD-1) deliver inhibitory signals when ... See full document
21
Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer
... objective response rate is higher than single agents ...encouraging response of the IDO inhibitors in combination with anti-PD-1 in many differ- ent solid tumors was observed in preclinical ... See full document
13
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
... targets PD-1, has been approved as a first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with positive PD-L1 ...However, PD-1/PD-L1 ... See full document
13
<p>Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle</p>
... with PD-1 blockade, the tumor growth of IDO knockout mice was signi fi cantly delayed, and the overall survival rate was improved compared with wild type ...83 Based on these studies, the ... See full document
12
Host expression of PD L1 determines efficacy of PD L1 pathway blockade–mediated tumor regression
... Therapeutic blockade of programmed death–ligand 1 (PD-L1, B7-H1) or programmed death protein 1 (PD-1) with mAbs leads to durable tumor control in a minority of patients ... See full document
12
The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies
... of PD-1 and PD-L1 expression character- istics in leukemia and lymphomas with defective T-cell immune responses have implications for the design of T- cell-based cancer immunotherapy, ... See full document
6
PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse
... of PD-1/PD-L1 and the immune response associated with the PD-1 axis in the datamining analysis, we investigated whether blockade of the PD-1 axis ... See full document
13
Clinical heterogeneity of hypophysitis secondary to PD-1/PD-L1 blockade: insights from four cases
... of PD-1-related hypophysitis, however, are appearing in the literature, highlighting the uniqueness of this type of toxicity, the distinction with the CTLA4-related hypophysitis (3), and the overall ... See full document
6
Hyperprogression after anti-programmed cell death ligand-1 therapy in a patient with recurrent metastatic urothelial bladder carcinoma following first-line cisplatin-based chemotherapy: a case report
... on PD-L1 blockade monotherapy on December 19, ...receiving PD-L1 blockade monotherapy, the patient experienced unusually rapid disease progression demonstrated in repeated CT ... See full document
10
Orchestration of immune checkpoints in tumor immune contexture and their prognostic significance in esophageal squamous cell carcinoma
... determined as lymphocytes that infiltrated into cancer nests. The median TILs’ count was used as a cutoff to categorize each case into either a high ( + ) TILs group or a low (–) TILs group. Immune cells were identified ... See full document
12
Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination
... checkpoint blockade, immunologic memory was established in cured mice but not in treatment-naïve mice suggesting that the immune system in cured mice retained the ability to recognize tumor-associated antigens and ... See full document
17
Bacillus Calmette–Guérin and anti-PD-L1 combination therapy boosts immune response against bladder cancer
... After four decades of the successful application of BCG immunotherapy in NMIBC, anti-PD-L1 therapy has already shown great promise as a cancer immunotherapy for advanced BCa in recent years. The success and ... See full document
9
Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November–2 December, 2017, Naples, Italy)
... dabrafenib (a BRAF inhibitor) and trametinib (a MEK mitogen-activated protein kinase inhibitor), obesity was associated with improved outcomes [7]. Indeed, there was an inverse linear relationship between body mass index ... See full document
13
Highly Pathological Influenza A Virus Infection Is Associated with Augmented Expression of PD-1 by Functionally Compromised Virus-Specific CD8+ T Cells
... marker PD-1 (Fig. 7). PD-1 expres- sion was not affected by the addition of IL-6 to the culture during stimulation, nor did IL-6 affect the ability of G-CSF to induce PD-1 ... See full document
16
Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)
... and PD-L2 demonstrated that both BMS-8 and BMS-202 are specific for ...human PD-L2 (hPD-L2) is available to date and only murine PD- L2 (mPD-L2) extracellular domain was crystallized in an apo form ... See full document
13
Related subjects